TrialAnnals of the rheumatic diseases2016

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Christopher J Edwards et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.